However, the clinical studies of ACTR087 with a 4-1BB-containing receptor combined with an anti-BCMA MoAb, SEA-BCMA in MM or other hematologic malignancy were halted due to safety concerns (NCT03266692) [57]. This evidence concerns the gene TNFRSF17 and Miyoshi myopathy.